These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peptides for nucleic acid delivery. Lehto T; Ezzat K; Wood MJA; El Andaloussi S Adv Drug Deliv Rev; 2016 Nov; 106(Pt A):172-182. PubMed ID: 27349594 [TBL] [Abstract][Full Text] [Related]
4. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs. Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616 [TBL] [Abstract][Full Text] [Related]
5. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. Lönnberg H Bioconjug Chem; 2009 Jun; 20(6):1065-94. PubMed ID: 19175328 [TBL] [Abstract][Full Text] [Related]
6. [Oligonucleotide therapeutics - an emerging novel class of compounds]. Wacheck V Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803 [TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide-based therapeutic options against hepatitis C virus infection. Trepanier JB; Tanner JE; Alfieri C Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043 [TBL] [Abstract][Full Text] [Related]
8. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). Hope MJ; Mui B; Ansell S; Ahkong QF Mol Membr Biol; 1998; 15(1):1-14. PubMed ID: 9595549 [TBL] [Abstract][Full Text] [Related]
9. Delivery of therapeutic oligonucleotides with cell penetrating peptides. Boisguérin P; Deshayes S; Gait MJ; O'Donovan L; Godfrey C; Betts CA; Wood MJ; Lebleu B Adv Drug Deliv Rev; 2015 Jun; 87():52-67. PubMed ID: 25747758 [TBL] [Abstract][Full Text] [Related]
14. Targeted delivery systems for oligonucleotide therapeutics. Yu B; Zhao X; Lee LJ; Lee RJ AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227 [TBL] [Abstract][Full Text] [Related]
15. Can colorectal delivery technology provide a platform for enteral oligonucleotide-based therapeutics? Murakami M; Watanabe C Drug Discov Ther; 2016; 10(5):273-275. PubMed ID: 27890901 [TBL] [Abstract][Full Text] [Related]
16. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
17. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Lee SH; Castagner B; Leroux JC Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313 [TBL] [Abstract][Full Text] [Related]
18. Building oligonucleotide therapeutics using non-natural chemistries. Wilson C; Keefe AD Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298 [TBL] [Abstract][Full Text] [Related]
19. The Medicinal Chemistry of Therapeutic Oligonucleotides. Wan WB; Seth PP J Med Chem; 2016 Nov; 59(21):9645-9667. PubMed ID: 27434100 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Mangla P; Vicentini Q; Biscans A Cells; 2023 Sep; 12(18):. PubMed ID: 37759475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]